Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 1 country.
Zeid J KhitanJoan C. Edwards School of Medicine, Marshall University, United States.
Imran KhawajaJoan C. Edwards School of Medicine, Marshall University, United States.
Maurice A MufsonJoan C. Edwards School of Medicine, Marshall University, United States.
Juan R SanabriaJoan C. Edwards School of Medicine, Marshall University, United States.
Nader G AbrahamNew York Medical College, Touro University, United States.
Stephen J PetersonNew York Presbyterian Brooklyn Methodist Hospital/Weill Cornell Medicine, United States.
Uma SundaramJoan C. Edwards School of Medicine, Marshall University, United States.
Joseph I ShapiroJoan C. Edwards School of Medicine, Marshall University, United States. Electronic address: shapiroj@marshall.edu.
Marshall University · USNew York Medical College · USNewYork–Presbyterian Brooklyn Methodist Hospital · US
Funding
Vasoregulatory Function of CYP2E1-Derived EicosanoidsP01HL034300 · NHLBI · NEW YORK MEDICAL COLLEGE · PI SCHWARTZMAN, MICHAL LANIADO · 1985 to 2015
$33.4M
CORAL: Clinical Coordinating CenterU01HL071556 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COOPER, CHRISTOPHER J · 2004 to 2013
$19.3M
Regulation of Tight Junction Molecular Composition by Na/K-ATPaseP20GM121299 · NIGMS · MARSHALL UNIVERSITY · PI HAYNES, JENNIFER · 2018 to 2022
$10.6M
Receptor Na/K-ATPase Antagonists As Novel Therapeutics For Renal/Cardiac DiseasesR01HL109015 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SHAPIRO, JOSEPH ISAAC, XIE, ZIJIAN · 2011 to 2014
$2.2M
Na/K-ATPase Reduction in Renal Disease-Related Cardiac DysfunctionR01HL105649 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI TIAN, JIANG · 2012 to 2016
COVID-19 infection causes considerable morbidity and mortality, especially to those who are aged, have impaired renal function and are obese. We propose to examine the potential utility of oral activated charcoal with the hypothesis that such treatment would lower absorption of microbiome derived toxins and ameliorate systemic oxidant stress and inflammation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Can charcoal improve outcomes in COVID-19 infections? · full record | OpenQuestion